PVLA Latest Press Releases

-- November 5, 2026 --

Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- November 3, 2026 --

Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference Globe Newswire 7:30 AM

-- October 29, 2026 --

Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026 Globe Newswire 7:30 AM

-- October 28, 2026 --

Palvella Announces FDA Acceptance and Priority Review of QTORIN Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set Globe Newswire 7:30 AM

-- October 15, 2026 --

Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference Globe Newswire 7:30 AM

-- October 13, 2026 --

Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference Globe Newswire 7:30 AM

-- October 12, 2026 --

Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026 Globe Newswire 7:30 AM

-- September 28, 2026 --

U.S. Food and Drug Administration Awards Additional Funding for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- September 17, 2026 --

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth Business Wire 8:32 AM

-- September 9, 2026 --

Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer Globe Newswire 7:30 AM

-- September 2, 2026 --

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences Globe Newswire 7:30 AM

-- August 31, 2026 --

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- August 5, 2026 --

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference Globe Newswire 7:30 AM

-- August 4, 2026 --

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- July 30, 2026 --

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing Globe Newswire 7:30 AM

-- July 28, 2026 --

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 Globe Newswire 7:30 AM

-- June 30, 2026 --

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors Globe Newswire 7:30 AM

-- June 29, 2026 --

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- June 22, 2026 --

FDA Grants Rolling Review of Palvella's QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- June 9, 2026 --

ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors PRNewswire 8:43 AM

Market Data Delayed 15 Minutes